Centricity Vision Inc., a global ophthalmic technology company dedicated to delivering solutions that help surgeons achieve surgical and clinical excellence, announced that Jim Mazzo has been appointed to the company’s Board of Directors.
 
Mazzo is one of the ophthalmic industry’s best known and most well respected business leaders with over 40 years of proven experience. His global reputation for building and running organizations is based on 22 years leading Allergan’s North American and European eye care organizations; seven years as chairman, president and CEO of Advanced Medical Optics (AMO); four years as executive vice president of Abbott’s global ophthalmology business; three years as executive chair and CEO of AcuFocus and nearly four years as global president of Ophthalmic Devices for Carl Zeiss Meditec.
 
“Jim will provide valuable strategic guidance and insight as we expand our vision care pipeline. We are grateful for his support and confidence in our team, technology and company vision,” said Rob Thornhill, president and CEO of Centricity Vision. “I am excited and honored to have Jim join our board as we execute our mission of creating a suite of next-generation ophthalmic capsular management devices.”
 
Currently, Mazzo serves as an advisor for Carl Zeiss Meditec’s Strategic Business Unit Ophthalmic Devices, which includes Ophthalmic Diagnostics, Surgical Ophthalmology and Refractive Lasers; executive chairman of Neurotech, a retinal implant company; and chairman for Avellino Labs, a biotechnology and genetic science company. Additionally, he is founder and chairman of OCTANe; a member of the International Intraocular Implant Club (lllC); serves as Leerink’s special advisor for Medical Devices; and is an Executive Committee Board Member with the Medical Device Manufacturers Association (MDMA). Mazzo also serves on several advisory boards, including the American Society of Cataract and Refractive Surgery (ASCRS) Governing Board, the American Academy of Ophthalmology (AAO) Foundation Advisory Board, the International Council of Ophthalmology (ICO) Foundation Advisory Board and the American Glaucoma Society (AGS) Foundation Advisory Board.
 
“Centricity Vision’s technology represents an important and unparalleled opportunity to revolutionize ophthalmology and advance cataract surgery. The ZEPTO Platform is already being used by some of the world’s most prominent ophthalmic surgeons, helping restore vision for the millions of people living with cataracts,” said Mazzo. “I am excited to join Centricity Vision’s Board of Directors and look forward to working with this exceptional team to increase global access to the ZEPTO Platform.”
 
The ZEPTO Precision Cataract Surgery Platform enables consistent, visual axis-centered, high-quality anterior capsulotomies during cataract surgery. ZEPTO integrates seamlessly into the routine steps of cataract surgery without increasing operative time or space requirements. The ZEPTO platform consists of a disposable handpiece and a small, inexpensive control console. The ZEPTO precision pulse capsulotomy technology utilizes a proprietary energy control algorithm to deliver a four-millisecond energy pulse, in combination with calibrated suction, to produce highly accurate, reproducible and strong-edged capsulotomies. ZEPTO performs equally as well in standard or difficult cases and is ideal for cataract patients choosing premium or non-premium lenses.
 
ZEPTO is available directly through the company’s sales and practice support team in the United States, as well as through select distributors in Europe and Asia.